MannKind Stock Surges Pre-Market Fueled by Promising Nintedanib DPI Trial Results, Driving Retail Optimism

Shares of MannKind Corp. ($MNKD) rose over 1% in pre-market trading on Monday following the announcement of the successful completion of its Phase 1 trial for Nintedanib Dry Powder Inhaler (DPI), aimed at treating pulmonary fibrotic diseases. 

MannKind develops inhaled therapeutics and devices for people with endocrine and lung diseases. Its shares have been rallying for the last six trading sessions, hitting an all-time high of $7.30 on Friday. 

The company believes its new delivery method for Nintedabid could effectively treat idiopathic pulmonary fibrosis (IPF) while minimizing the common side effects linked to the same oral medication, such as gastrointestinal or neurological issues.

"These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said MannKind CEO Michael Castagn in a press statement.

The study involved 40 healthy adults and aimed to assess the safety of the drug. 

MannKind plans to meet with the Food and Drug Administration (FDA) in the first half of 2025 to discuss the trial results and the next steps for developing Nintedanib DPI. 

Retail investors on Stocktwits are largely optimistic about MannKind's stock, expressing a predominantly bullish sentiment.

https://stocktwits.com/ItzaFugazi/message/591069868 

Users view the company’s stock as a compelling opportunity in the biopharmaceutical sector. 

https://stocktwits.com/MrMulally/message/591069985 

MannKind’s stock value has gained 84% so far in 2024 and nearly doubled in value over the last 12 months. 

For updates and corrections email newsroom@stocktwits.com.

Read also: MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic